Juno Therapeutics, Inc. (NASDAQ:JUNO) was upgraded by SunTrust Banks, Inc. from a “hold” rating to a “buy” rating in a research note issued on Thursday, November 2nd, MarketBeat.com reports.
Several other research firms have also issued reports on JUNO. Zacks Investment Research lowered Juno Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd. Morgan Stanley increased their target price on Juno Therapeutics from $26.00 to $27.00 and gave the stock an “equal weight” rating in a research note on Monday, August 7th. Vetr lowered Juno Therapeutics from a “hold” rating to a “sell” rating and set a $28.47 target price on the stock. in a research note on Monday, August 7th. Cowen and Company reissued a “buy” rating and set a $49.00 target price on shares of Juno Therapeutics in a research note on Friday, October 27th. Finally, ValuEngine upgraded Juno Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 29th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $44.20.
Shares of Juno Therapeutics (JUNO) traded down $0.29 during trading on Thursday, hitting $58.77. The stock had a trading volume of 1,668,249 shares, compared to its average volume of 2,053,920. Juno Therapeutics has a twelve month low of $17.52 and a twelve month high of $61.59. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01.
Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The business had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. During the same quarter in the prior year, the company posted ($0.57) EPS. The company’s quarterly revenue was up 115.4% on a year-over-year basis. equities analysts forecast that Juno Therapeutics will post -4.02 earnings per share for the current fiscal year.
WARNING: This article was originally reported by BBNS and is owned by of BBNS. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://baseballnewssource.com/markets/juno-therapeutics-inc-juno-lifted-to-buy-at-suntrust-banks-inc/1751627.html.
In other Juno Therapeutics news, General Counsel Bernard J. Cassidy sold 28,000 shares of the stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $44.92, for a total transaction of $1,257,760.00. Following the completion of the sale, the general counsel now directly owns 55,970 shares of the company’s stock, valued at approximately $2,514,172.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Sunil Agarwal sold 7,285 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $44.76, for a total value of $326,076.60. The disclosure for this sale can be found here. Insiders have sold a total of 79,670 shares of company stock valued at $3,553,777 over the last ninety days. 15.26% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Utah Retirement Systems lifted its holdings in shares of Juno Therapeutics by 1.8% in the 2nd quarter. Utah Retirement Systems now owns 11,600 shares of the biopharmaceutical company’s stock valued at $347,000 after buying an additional 200 shares during the period. State of Wisconsin Investment Board lifted its holdings in shares of Juno Therapeutics by 1.7% in the 2nd quarter. State of Wisconsin Investment Board now owns 12,562 shares of the biopharmaceutical company’s stock valued at $375,000 after buying an additional 210 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Juno Therapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 228 shares during the period. Aperio Group LLC lifted its holdings in shares of Juno Therapeutics by 4.2% in the 3rd quarter. Aperio Group LLC now owns 29,554 shares of the biopharmaceutical company’s stock valued at $1,326,000 after buying an additional 1,194 shares during the period. Finally, SG Americas Securities LLC lifted its holdings in shares of Juno Therapeutics by 9.5% in the 3rd quarter. SG Americas Securities LLC now owns 15,254 shares of the biopharmaceutical company’s stock valued at $684,000 after buying an additional 1,328 shares during the period. 66.96% of the stock is owned by institutional investors and hedge funds.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with our FREE daily email newsletter.